Actively Recruiting
Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-01-13
150
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase II clinical trial of PD-L1 in combination with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy with or without radiotherapy for advanced triple-negative breast cancer.
CONDITIONS
Official Title
Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older at signing informed consent
- Diagnosed with metastatic triple-negative breast cancer with clear clinical data per ASCO/CAP guidelines
- Received one or fewer lines of chemotherapy for metastatic breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days before treatment
- At least one measurable lesion according to RECIST v1.1 guidelines
- Prior treatment with anthracyclines and/or taxanes allowed under specified conditions
- Female participants are not pregnant or lactating and agree to use contraception
- Ability to provide informed consent
- Appropriate organ function confirmed by laboratory tests within 10 days before treatment start
You will not qualify if you...
- None explicitly stated in the provided eligibility criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
2
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
F
Fei Ma 马
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here